Whereas the use of an anti-CCL2 monoclonal antibody reduced both the growth of primary malignant lesions and the metastases number in an implantable tumor model, CCL2 or CCR2 knockout mice developed transgenic tumors and had an increased number of metastases [165]. Here, CCR2 is linked to neoplasm.